Monitor for future prospectus supplements that will disclose actual offering size, pricing, and use of proceeds. The effectiveness of the S-3 enables flexible capital raising, which could lead to near-term dilution if shares are issued.
RCKT drugs
RCKT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 11 $4.96entry
- T+1 · 8mo ago −0.81%α +0.68% · $4.92
- T+5 · 8mo ago −9.88%α −7.69% · $4.47
- T+20 · 7mo ago −27.42%α −27.94% · $3.60
- T+60 · 6mo ago −41.13%α −52.65% · $2.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rocket Pharmaceuticals, Inc. has an effective shelf registration (Form S-3) as of March 10, 2026, allowing the company to issue unspecified securities from time to time. This creates a potential for future dilution, though no specific offering size or terms were disclosed.
Key Facts
- Form S-3 shelf registration became effective on March 10, 2026.
- The filing is a general offering statement, permitting the company to sell securities in one or more offerings without filing a new registration.
- No specific offering size, pricing, or use of proceeds was disclosed in this filing.
- The company may issue common stock, preferred stock, debt, or warrants under this shelf.
Financial Impact
Not specified
Risk Factors
- Potential for unexpected equity issuance leading to shareholder dilution.
- Market perception of a dilution overhang may pressure the stock price ahead of any offering.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-000767 |
| Document: 9999999995-26-000767-index.html | 9999999995-26-000767 |
| Document: 9999999995-26-000767.txt | 9999999995-26-000767 |
Track record
21 reports on RCKT
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +42.18% at T+20 after the Jun 12, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.45 Now $2.16 −11.84% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $2.44 Now $2.16 −11.29% settles Dec 4
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $2.44 Now $2.16 −11.48% settles Nov 30
- Oct 6, 20265w ago 8-K Bullish 7/10 Entry $2.54 to $2.57 Now $2.16 −14.79% ▲ +1.38% +2.62% vs SPY
- Sep 15, 20268w ago 8-K Bullish 7/10 Entry $3.41 to $2.30 Now $2.16 −36.66% ▼ −32.55% −35.27% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers